Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations

BACKGROUND: Non-small cell lung cancer (NSCLC) patients that harbor epidermal growth factor receptor (EGFR) mutations benefit from receiving an EGFR-tyrosine kinase inhibitor (TKI); however, post-progression survival (PPS) after EGFR-TKI treatment has not been sufficiently studied. METHODS: We retro...

Descripción completa

Detalles Bibliográficos
Autores principales: Kogure, Yoshihito, Saka, Hideo, Oki, Masahide, Saito, Toshiki I., Ahmed, Shimaa Nour Moursi, Kitagawa, Chiyoe, Imaizumi, Kazuyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532435/
https://www.ncbi.nlm.nih.gov/pubmed/26262682
http://dx.doi.org/10.1371/journal.pone.0135393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532435/
https://www.ncbi.nlm.nih.gov/pubmed/26262682
http://dx.doi.org/10.1371/journal.pone.0135393

Ejemplares similares